Short Communication

*Author for correspondence: Tel.: +81 72 922 0881;

https://orcid.org/0000-0002-1369-4713

Department of Pediatrics, Yao Municipal Hospital, Osaka, Japan

Search for more papers by this author

Keigo Saeki

https://orcid.org/0000-0001-6465-8205

Department of Epidemiology, Nara Medical University School of Medicine, Nara, Japan

Search for more papers by this author

Ichiro Tanaka

https://orcid.org/0000-0001-6947-0068

Department of Pediatrics, Yao Municipal Hospital, Osaka, Japan

Search for more papers by this author

Published Online:26 Mar 2024https://doi.org/10.2217/imt-2024-0024

View article

Abstract

Aim: We compared the effectiveness of rush subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) using standardized house dust mite (HDM) extract for pediatric bronchial asthma (BA). Methods: We followed the pediatric BA treatment score during 3 years of treatment. We assessed the median time to no longer requiring long-term control pharmacotherapy (LTCP) for BA (LTCP-free). We compared the outcomes after adjustment for confounding factors and propensity score matching. Results: Patients in the HDM SCIT group achieved the LTCP-free status significantly earlier than those in the HDM SLIT group after adjustment for confounding factors and propensity score matching. Conclusion: Patients treated for pediatric BA with rush HDM SCIT had earlier onset of therapeutic effects than those with HDM SLIT.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Levy ML, Bacharier LB, Bateman E et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim. Care Respir. Med. 2023;33(1):7. doi: 10.1038/s41533-023-00330-1.
MedlineGoogle Scholar
2. Stern DA, Morgan WJ, Halonen M et al. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 2008;372(9643):1058–1064. doi: 10.1016/S0140-6736(08)61447-6.
MedlineGoogle Scholar
3. Horak E, Lanigan A, Roberts M et al. Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42. BMJ 2003;326(7386):422–423. doi: 10.1136/bmj.326.7386.422.
MedlineGoogle Scholar
4. McGeachie MJ, Yates KP, Zhou X et al. Patterns of growth and decline in lung function in persistent childhood asthma. N. Engl. J. Med. 2016;374(19):1842–1852. doi: 10.1056/NEJMoa1513737.
Medline CASGoogle Scholar
5. To M, Tsuzuki R, Katsube O et al. Persistent Asthma from Childhood to Adulthood Presents a Distinct Phenotype of Adult Asthma. J. Allergy Clin. Immunol. Pract. 2020;8(6):1921–1927. doi: 10.1016/j.jaip.2020.01.011.
MedlineGoogle Scholar
6. Fuchs O, Bahmer T, Rabe KF et al. Asthma transition from childhood into adulthood. Lancet Respir. Med. 2017;5(3):224–234. doi: 10.1016/S2213-2600(16)30187-4.
MedlineGoogle Scholar
7. Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S et al. EAACI allergen immunotherapy User's guide. Pediatr. Allergy Immunol. 2020;31(Suppl. 25):1–101. doi: 10.1111/pai.13189.
MedlineGoogle Scholar
8. Arakawa H, Hamasaki Y, Kohno Y et al. Japanese guidelines for childhood asthma 2017. Allergol. Int. 2017;66(2):190–204. doi: 10.1016/j.alit.2016.11.003.
MedlineGoogle Scholar
9. Okubo K, Kurono Y, Ichimura K et al. Japanese guidelines for allergic rhinitis 2020. Allergol. Int. 2020;69(3):331–345. doi: 10.1016/j.alit.2020.04.001.
Medline CASGoogle Scholar
10. Cox L, Larenas-Linnemann D, Lockey RF et al. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J. Allergy Clin. Immunol. 2010;125(3):569–574. doi: 10.1016/j.jaci.2009.10.060.
MedlineGoogle Scholar
11. Hamada M, Saeki K, Tanaka I. Effectiveness and safety of subcutaneous immunotherapy with standardized house dust mite extract for patients under the age of 5 years: a prospective cohort study. Allergol. Int. 2021;70(4):492–494. doi: 10.1016/j.alit.2021.05.004.
MedlineGoogle Scholar
12. Hamada M, Saeki K, Tanaka I. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: a prospective cohort study. Allergol. Int. 2023;72(4):573–579. doi: 10.1016/j.alit.2023.02.007.
Medline CASGoogle Scholar
13. Takai T, Okamoto Y, Okubo K et al. Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines-secondary publication. Allergol. Int. 2015;64(2):181–186. doi: 10.1016/j.alit.2015.01.005.
Medline CASGoogle Scholar
14. Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Stat. Med. 2023;42(10):1461–1479. doi: 10.1002/sim.9681.
MedlineGoogle Scholar
15. Denz R. adjustedCurves: confounder-adjusted survival curves and cumulative incidence functions. R package verion0.9.0 (2023). Available at: https://cran.r-project.org/package=adjutedCurves
Google Scholar
16. Pepe MS, Fleming TR. Weighted Kaplan-Meier Statistics: a class of distance tests for censored survival data. Biometrics 1989;45(2):497–507.
Medline CASGoogle Scholar
17. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244.
Medline CASGoogle Scholar
18. Dhami S, Kakourou A, Asamoah F et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 2017;72(12):1825–1848. doi: 10.1111/all.13208.
Medline CASGoogle Scholar
19. Keles S, Karakoc-Aydiner E, Ozen A et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J. Allergy Clin. Immunol. 2011;128(4):808–815. doi: 10.1016/j.jaci.2011.04.033.
Medline CASGoogle Scholar
20. Karakoc-Aydiner E, Eifan AO, Baris S et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J. Investig Allergol. Clin. Immunol. 2015;25(5):334–342.
Medline CASGoogle Scholar
21. Hamada M. Evaluation of protocols for rush subcutaneous immunotherapy with standardized house dust mite extracts. Arelugi 2020;69(1):40–47. doi: 10.15036/arerugi.69.40.
Google Scholar
22. Okamoto Y, Kato M, Ishii K et al. Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan. Immunotherapy 2023;15(16):1401–1414. doi: 10.2217/imt-2023-0100. • Investigates the reasons for discontinuation of house dust mite sublingual immunotherapy in a real-world setting, based on numerous cases.
CASGoogle Scholar
23. Plewako H, Wosinska K, Arvidsson M et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int. Arch. Allergy Immunol. 2006;141(4):346–353. doi: 10.1159/000095461. •• Reports the early suppression of basophils in rush allergen immunotherapy, a subset of allergen immunotherapy.
Medline CASGoogle Scholar
24. Novak N, Mete N, Bussmann C et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J. Allergy Clin. Immunol. 2012;130(5):1153–1158. doi: 10.1016/j.jaci.2012.04.039.
Medline CASGoogle Scholar
25. Van Overtvelt L, Baron-Bodo V, Horiot S et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy 2011;66(12):1530–1537. doi: 10.1111/j.1398-9995.2011.02696.x.
Medline CASGoogle Scholar
26. Ciepiela O, Zawadzka-Krajewska A, Kotula I et al. Sublingual immunotherapy for asthma: affects T-cells but does not impact basophil activation. Pediatr. Allergy Immunol. Pulmonol. 2014;27(1):17–23. doi: 10.1089/ped.2014.0328.
MedlineGoogle Scholar

Ahead of Print

Supplemental Materials

Metrics

Downloaded 20 times

History

Received 23 January 2024

Accepted 11 March 2024

Published online 26 March 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2024-0024

Author contributions

MH designed the study and wrote the initial draft of the manuscript. IT and KS assisted in the preparation of the manuscript and critically reviewed the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

We thank all patients and their parents who participated in this study.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma

Abstract

References